Barclays’s Kite Pharma, Inc. KITE Stock Holding History

Barclays’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-300,500	Closed	-$54M	–	7354
2017 Q3	$54M	Buy	+300,500	New	+$41.9M	0.06%	274
2016 Q4	–	Sell	-120,000	Closed	-$6.7M	–	7028
2016 Q3	$6.7M	Buy	+120,000	New	+$6.69M	0.01%	1090
2015 Q4	–	Sell	-6,000	Closed	-$330K	–	7002
2015 Q3	$330K	Buy	+6,000	New	+$377K	﹤0.01%	3721

Barclays's KITE Position: Q4 2017 in Review

Barclays sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 48,607 shares — an estimated $8.74M sold.

Barclays first reported a position in KITE in Q4 2014 and held it in 11 quarters. The position peaked at $8.74M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

Barclays reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
Barclays sold 48,607 Kite Pharma, Inc. shares in Q4 2017, an estimated $8.74M.
Barclays first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 11 quarters.
Barclays's Kite Pharma, Inc. position peaked at $8.74M in Q3 2017.
0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.